iShares US Pharmaceuticals ETF
IHE
IHE
130 hedge funds and large institutions have $140M invested in iShares US Pharmaceuticals ETF in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 32 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
7.34% more ownership
Funds ownership: 92.89% → 100.23% (+7.3%)
3% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 32
Holders
130
Holding in Top 10
–
Calls
$651K
Puts
$242K
Top Buyers
| 1 | +$4.08M | |
| 2 | +$3.73M | |
| 3 | +$3.14M | |
| 4 |
Goldman Sachs
New York
|
+$2.49M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.84M |
Top Sellers
| 1 | -$4.17M | |
| 2 | -$2.85M | |
| 3 | -$2.79M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$663K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$474K |